Latest news with #BectonDickinson
Malaysian Reserve
3 days ago
- Health
- Malaysian Reserve
Women's Health Diagnostics Market Hits $14.6 Billion-Kalorama Information Report Reveals Key Growth Drivers to 2030
Comprehensive analysis reveals emerging opportunities in imaging, molecular diagnostics, and AI-driven tools as women's health takes center stage in global care strategies. ARLINGTON, Va., July 17, 2025 /PRNewswire/ — Kalorama Information, a leading healthcare market research firm, has released its latest report, Women's Health Diagnostic Markets: Global Outlook and Forecast to 2030. This in-depth analysis examines the current and projected global markets for diagnostic tests uniquely relevant to women's health, offering vital insights for diagnostic companies, investors, and healthcare stakeholders seeking to capitalize on evolving clinical and consumer needs. As global life expectancy for women continues to rise—and as women account for over 75% of healthcare decision-making in U.S. households—the report emphasizes a critical shift in medical diagnostics toward more personalized, sex-specific tools. Diagnostics are rapidly becoming the backbone of this transformation, enabling earlier detection, better outcomes, and more cost-effective care across the female lifespan. 'The global market for women's health test products is estimated to be worth $14.6 billion in 2024. This arena—once confined to obstetrics and gynecology—now spans specialties such as urology, maternal-fetal medicine, autoimmune and genetic disease,' said Justin Saeks, Senior Analyst at Kalorama Information. 'Diagnostics are essential to connecting patients to the right treatment at the right time, yet they remain one of the most cost-efficient parts of the healthcare system.' Key Takeaways from the Report Rising Global Adoption of NIPT: Non-invasive prenatal testing is now recommended for all U.S. pregnancies and is gaining ground globally. North America accounts for 44% of global NIPT revenues and is projected to grow at 8%+ CAGR through 2029. Mammography Market on the Rise: Driven by widespread breast cancer screening, the mammography systems segment—dominated by digital technology—is forecast to grow at a mid-single-digit CAGR through 2030. AI Transforms Diagnostic Imaging: Advances in deep learning are fueling the growth of computer-aided detection (CAD) tools, projected to expand by nearly 7% annually. Diagnostics Drive Over 70% of Medical Decisions, yet account for less than 5% of total healthcare costs—highlighting a high-impact, under-leveraged sector for innovation and investment. What's Inside the Report The report offers detailed segmentation and forecasts across major diagnostic categories: Imaging: Mammography, OB/GYN ultrasound, CADe/CADx Genetic and Prenatal Testing: NIPT, carrier screening Sexually Transmitted and Infectious Disease: HPV, TORCH, UTI diagnostics Fertility & Pregnancy: POC and lab-based fertility, ovulation, pregnancy testing Cancer and Autoimmune: Pap tests, ovarian cancer biomarkers, autoimmune immunoassays Preventive Diagnostics: Bone densitometry, colposcopy systems Companies Profiled: Becton Dickinson (BD), Hologic, GE HealthCare, Roche, Siemens Healthineers, Thermo Fisher Scientific, and emerging players across key sectors. Who Should Read This Report This report is a must-read for: IVD and Device Manufacturers planning next-gen products in imaging, POC, or molecular diagnostics Pharma and Biotech Firms seeking companion diagnostics for women-targeted therapies Investors and M&A Teams identifying high-growth diagnostic segments Healthcare Providers and Policymakers aiming to close the gap in women's health equity Commercial and Strategy Leaders aligning messaging, product roadmaps, and reimbursement strategies Availability & Contact Information Explore the report: Women's Health Diagnostic Markets: Global Outlook and Forecast to 2030 is available now from Kalorama Information. View Table of Contents / Purchase Report For inquiries and custom consultations:Sheri Davie – Sales For media inquiries:Richa Singh – VP, Strategic & Insights About Kalorama Information Kalorama Information, part of Science and Medicine Group, is a premier source for healthcare market intelligence. For over 25 years, Kalorama has delivered trusted insights on in vitro diagnostics (IVD), clinical testing, and emerging medical technologies, including its industry-leading title, The Worldwide Market for In Vitro Diagnostic Tests. To learn more, visit:
Wall Street Journal
6 days ago
- Business
- Wall Street Journal
Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks
A deal for Becton Dickinson's BDX 1.60%increase; green up pointing triangle biosciences and diagnostic solutions unit puts Waters Corp. WAT -4.94%decrease; red down pointing triangle in a greater position to compete with larger life-science companies, but integration risks can't be discounted, analysts say. The maker of lab equipment and software on Monday agreed to pay around $17.5 billion for the unit of medical-device maker Becton. Waters shares closed the day at $304.18, down 14%.
Yahoo
6 days ago
- Business
- Yahoo
Waters deal adds variables to ‘clean' story, says Jefferies
Jefferies expects shares of Waters (WAT) to trade down on the combination with Beckton Dickinson (BDX) via a reverse merger trust due to the deal size and 'variables added to a clean replacement cycle story.' However, longer term, Jefferies likes the merits of the deal, saying it creates real scale, which has proven effective in the space. It keeps a Buy rating on Waters, which is trading down 13% to $306.92 in morning trading. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on WAT: Disclaimer & DisclosureReport an Issue Waters falls -9.0% Waters sinks 12% to $312.06 following combination with Becton unit Hold Rating on Waters-Becton Merger: Strategic Growth vs. Valuation Concerns Waters, BD's Biosciences & Diagnostic Solutions business to combine Waters Announces $17.5B Merger with BD's Biosciences
Yahoo
7 days ago
- Business
- Yahoo
S&P 500 Gains & Losses Today: EQT Stock Jumps, Modelo Maker Constellation Drops
The S&P 500 ticked 0.1% higher on Monday, July 14, 2025. Trade policy remained in the spotlight to kick off a week that also feature several earnings and economic reports. EQT shares advanced as natural gas futures prices soared, bolstered by declines in production and shifting weather forecasts. Waters stock sank after the lab equipment maker announced a deal to purchase Becton Dickinson's Biosciences & Diagnostic Solutions U.S. equities indexes edged higher to open a new week of trading that will include earnings reports from major financial institutions and key inflation data—while ongoing trade negotiations keep the tariff landscape in a state of constant evolution. The S&P 500 added around 0.1%, ending Monday's session just beneath the all-time closing high set last Thursday. A gain of 0.3% was enough to lift the tech-heavy Nasdaq to a record close, while the Dow industrials gained 0.2%. Read Investopedia's full daily markets coverage here. Natural gas futures prices pushed 4% higher, with analysts pointing to indications of tightening in the market including a decline in production and an uptick in implied weather-driven demand. Shares of natural gas producer and pipeline operator EQT Corp. (EQT) advanced 5.3%, securing the S&P 500's top performance on Monday. Analysts at RBC Capital, Jefferies and Scotiabank lifted their price targets on EQT's stock last week. Autodesk (ADSK) shares gained more than 5% following reports that the company is no longer pursuing an acquisition of engineering design software competitor PTC (PTC). Autodesk stock came under pressure late last week after Bloomberg reported that the company was discussing a possible cash-and-stock purchase of its rival. However, Autodesk said in a regulatory filing that it would remain focused on its strategy, which might include "targeted and tuck-in acquisitions," with no direct mention of PTC. Shares of PTC slipped 1.3%. Shares of data analytics software provider Palantir Technologies (PLTR) jumped 5%, finishing at an all-time high. Toward the end of last week, Wedbush boosted its price target on Palantir stock, saying the company could be a primary beneficiary from the expected surge in spending on artificial intelligence technology. The analysts believe investors could be underestimating the potential revenue stream from Palantir's Artificial Intelligence Platform, or AIP, which Wedbush pegs at $1 billion or more. Laboratory instrument manufacturer Waters (WAT) announced a deal to buy the Biosciences & Diagnostic Solutions division of Becton Dickinson (BDX) in a $17.5 billion Reverse Morris Trust transaction. The acquisition, of a business that makes products for treating infectious diseases and cancer, promises to boost scale and increase the total addressable market for Waters, but analysts pointed to execution and integration risks. Waters shares plunged 13.8%, the most of any stock in the S&P 500. Shares of memory chipmaker Micron Technology (MU) slipped 4.8%. Edgewater Research indicated that pricing and demand for computer memory chips could be below seasonal trends in the second half of 2025. Shares of Micron rival SanDisk (SNDK) tumbled 7.8%. Constellation Brands (STZ) shares sank 4.4% as investors grappled with the latest intensification of trade tensions and tariff news. The beer, wine, and spirits maker depends on aluminum cans for its packaging, particularly when it comes to its popular Mexican beer brands Corona and Modelo. At the beginning of June, Constellation indicated that aluminum tariffs would cost the company approximately $20 million throughout the rest of its fiscal year. Read the original article on Investopedia Sign in to access your portfolio
Yahoo
7 days ago
- Business
- Yahoo
Why Waters Corporation (WAT) Stock Is Down Today
Shares of scientific instruments company Waters Corporation (NYSE:WAT) fell 12.8% in the morning session after the company announced a definitive agreement to merge with the Biosciences & Diagnostic Solutions business of Becton, Dickinson and Company (BDX) in a deal valued at approximately $17.5 billion. The transaction was structured as a Reverse Morris Trust, a tax-efficient way to combine the two entities. Upon completion, current Waters shareholders are expected to own about 60.8% of the new, larger company. While the deal was intended to create a life science and diagnostics leader, the significant drop in share price suggests investor apprehension. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Waters Corporation? Access our full analysis report here, it's free. Waters Corporation's shares are not very volatile and have only had 8 moves greater than 5% over the last year. Moves this big are rare for Waters Corporation and indicate this news significantly impacted the market's perception of the business. Waters Corporation is down 15.3% since the beginning of the year, and at $312.09 per share, it is trading 25.2% below its 52-week high of $417.28 from January 2025. Investors who bought $1,000 worth of Waters Corporation's shares 5 years ago would now be looking at an investment worth $1,575. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
